Allogeneic stem cell transplantation after reduced-intensity conditioning for acute myeloid leukaemia: Impact of chronic graft-versus-host disease

Current Opinion in Oncology

Volumn 21, Issue SUPPL. 1, 2009, Pages

  Valcárcel, David ^a,b   Martino, Rodrigo ^a   Piñana, Jose L ^a   Sierra, Jorge ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Allogeneic stem cell transplantation; Graft versus host disease; Graft versus tumour effect; Reduced intensity conditioning

Indexed keywords

AZACITIDINE; BUSULFAN; CYCLOSPORIN A; CYTOKINE; FLUDARABINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CD34 SELECTION; CHRONIC GRAFT VERSUS HOST DISEASE; DONOR LYMPHOCYTE INFUSION; HIGH RISK PATIENT; HLA MATCHING; HUMAN; LEUKEMIA RELAPSE; LIVING DONOR; LOW ENERGY RADIATION; MINIMAL RESIDUAL DISEASE; MYELODYSPLASTIC SYNDROME; NATURAL KILLER CELL; PATIENT MONITORING; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; SHORT SURVEY; SIBLING; T LYMPHOCYTE; TREATMENT OUTCOME; WHOLE BODY RADIATION;

CHRONIC DISEASE; GRAFT VS HOST DISEASE; GRAFT VS TUMOR EFFECT; HUMANS; LEUKEMIA, MYELOID, ACUTE; STEM CELL TRANSPLANTATION; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 68049127727     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cco.0000357474.66035.9b     Document Type: Short Survey

References (15)

1. Valcárcel D, Martino R, Sureda A, et al. Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies. Eur J Haematol 2005; 74:144-151.
2. Perez-Simon JA, Diez-Campelo M, Martino R, et al. Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-versus-host disease after allogeneic transplantation. Br J Haematol 2005; 130:394-403.
3. Mielcarek M, Martin PJ, Leisenring W, et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003; 102:756-762.
4. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging. Working Group Report. Biol Blood Marrow Transplant 2005; 11:945-956.
5. Martino R, Caballero MD, Simon JA, et al. Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes. Blood 2002; 100:2243-2245.
6. Baron F, Maris MB, Sandmaier B, et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol 2005; 23:1993-2003.
7. Valcárcel D, Martino R. Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and acute myelogenous leukemia. Curr Opin Oncol 2007; 19:660-666.
8. Lazarus HM, Rowe JM. Reduced-intensity conditioning for acute myeloid leukemia: is this strategy correct. Leukemia 2006; 20:1673-1682.
9. Hegenbart U, Niederwieser D, Sandmaier BM, et al. Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol 2006; 24:444-453.
10. Blaise DP, Michel BJ, Faucher C, et al. Reduced-intensity conditioning prior to allogeneic stem cell transplantation for patients with acute myeloblastic leukemia as a first-line treatment. Cancer 2005; 104:1931-1938.
11. Valcárcel D, Martino R, Caballero D, et al. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. J Clin Oncol 2008; 26:577-584.
12. Aoudjhane M, Labopin M, Gorin NC, et al. Comparative outcome of reduced-intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia 2005; 19:2304-2312.
13. Martino R, Iacobelli S, Brand R, et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood 2006; 108:836-846.
14. Herr A-L, Labopin M, Blaise D, et al. HLA-identical sibling allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning compared to autologous peripheral blood stem cell transplantation for elderly patients with de novo acute myeloid leukemia. Leukemia 2007; 21:129-135.
15. Mohty M, de Lavallade H, Ladaique P, et al. The role of reduced-intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia: a donor vs no donor comparison. Leukemia 2005; 19:916-920.